ProQR Therapeutics
PRQR
56 hedge funds and large institutions have $340M invested in ProQR Therapeutics in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 11 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
3.67% more ownership
Funds ownership: 61.3% → 64.97% (+3.7%)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
2% less funds holding
Funds holding: 57 → 56 (-1)
7% less capital invested
Capital invested by funds: $364M → $340M (-$24.8M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $27K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$48.9M |
| 2 |
O
OrbiMed
New York
|
+$8.13M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$7.27M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$4.32M |
| 5 |
Goldman Sachs
New York
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$45M |
| 2 |
Morgan Stanley
New York
|
-$3.52M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.24M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.84M |
| 5 |
Jennison Associates
New York
|
-$1.59M |
PRQR Hedge Fund Activity: Q1 2019 in Review
56 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2019, worth a combined $340M — down 6.8% from $364M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PRQR and 10 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 17 added.
The largest buyer was RTW Investments, adding an estimated $48.9M. The largest seller was UBS Group, exiting entirely with an estimated $45M sold.
- 56 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2019, down from 57 in Q4 2018.
- Funds reported $340M of ProQR Therapeutics stock for Q1 2019, down 6.8% quarter-over-quarter.
- 10 funds opened new ProQR Therapeutics positions in Q1 2019 and 11 closed out, a net change of -1 holder.
- The largest ProQR Therapeutics buyer in Q1 2019 was RTW Investments, an estimated $48.9M added.
- The largest ProQR Therapeutics seller in Q1 2019 was UBS Group, an estimated $45M sold.
Based on aggregated 13F filings for Q1 2019.